– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Newronika, a leader in neuromodulation and adaptive deep brain stimulation (DBS) technology, announced today that it has received CE Mark approval for its ...

ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Merck plans to launch US subcutaneous version of Keytruda on October 1 Healthcare & Pharmaceuticalscategory · 12:15 AM UTC · Updated ago The Merck logo ... US FDA approves first treatment ...

The Senate confirmed two of President Donald Trump’s health nominees Tuesday evening, largely along party lines, in a win for ...

Sanofi's subcutaneous, or under-the-skin, therapy helps prevent bleeding and lowers antithrombin, a protein that delays blood ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

March 28 (Reuters) - The U.S. Food and Drug Administration approved French drugmaker Sanofi's (SASY.PA), opens new tab hemophilia therapy, introducing a new type of treatment administered every ...

(Reuters) -The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of treatment administered every two months for patients with the rare ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...